Study design
| Groupa | No. of Animals | Compound | Samples Collected | Purpose | |
|---|---|---|---|---|---|
| BDC | Intact | ||||
| 1 | 0 | 12 | Pefloxacin | Blood | Plasma exposure by LC-MS/MS and 19F NMR |
| 2 | 0 | 6 | [14C]Pefloxacin | Blood | Metabolite profiling by radioactivity |
| 3 | 4 | 0 | Pefloxacin | Bile, urine, feces | Excretion and metabolite profiling by 19F NMR |
| 4 | 4 | 0 | [14C]Pefloxacin | Bile, urine, feces | Excretion and metabolite profiling by radioactivity |
| 5 | 0 | 4 | Pefloxacin | Blood and tissues | Distribution by 19F NMR |
| 6 | 0 | 4 | [14C]Pefloxacin | Blood and tissues | Distribution by radioactivity |
BDC, bile duct–cannulated.
↵a Administered pefloxacin dose was 25 mg/kg in all groups.